Columnist Ray Burow, grieving the loss of her dear friend Richard Allen Farmer, reflects on how he cared for her mother, who ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of so-called beta-amyloid fragments that stick together and accumulate ...

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

Experimental treatments being developed to address the underlying cause of Alzheimer’s disease mostly target beta-amyloid plaques and tau protein tangles, which are thought to be the main players in ...

For Alzheimer's Awareness Month this November, supporters are encouraged to wear teal and spread the word on social media to educate others.

Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in ...